Companies: 10,795·Total market cap: $144.5T
Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NWPHFOTCHealthcare
$20.00
+$0.00(+0.00%)
Market Cap$416115900
P/E Ratio
52W High$20
52W Low$9.36

Newron Pharmaceuticals S.p.A. (NWPHF) Revenue

Annual & quarterly revenue history · segment & region breakdown

NWPHF · revenue · updated Jun 9, 2026

Core revenue metrics

Newron Pharmaceuticals S.p.A. trailing twelve-month (TTM) revenue is $0.06B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.06B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
6.83×
mktCap ÷ TTM rev
Revenue per day
$0M
Est. TTM ÷ 365
Revenue / employee
$2768K
22 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Newron Pharmaceuticals S.p.A. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
NWPHF revenue by year · NWPHF revenue history · NWPHF annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Newron Pharmaceuticals S.p.A. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Newron Pharmaceuticals S.p.A. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Newron Pharmaceuticals S.p.A.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

NWPHF revenue · 4 questions

NWPHF's trailing twelve-month (TTM) revenue is $0.06B. That is an increase of 0.00% year-over-year from — in FY.

NWPHF revenueNWPHF annual revenuewhat is NWPHF revenueNWPHF TTM revenue

Source: FMP · Newron Pharmaceuticals S.p.A. SEC filings · GAAP · Newron Pharmaceuticals S.p.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026